Souza, Dyego Leandro Bezerra dePérez, Milagros BernalSoler, Ramón CleriesGómez-Bernal, German Jorge2023-10-162023-10-162016SOUZA, Dyego Leandro Bezerra de; PÉREZ, Milagros Bernal; SOLER, Ramón Cleries; BERNAL, Germán Gómez. Análisis de la supervivência relativa en cáncer. Años 2003-2009. Medicina Naturista, v. 10, p. 100-105, 2016. Disponível em: https://dialnet.unirioja.es/servlet/articulo?codigo=5591361 . Acesso em: 2 out. 20231576-3080https://repositorio.ufrn.br/handle/123456789/55001Background: To determine the survival of cancer allows a posteriori know the effectiveness and efficiency of the different treatments. The current justification is essential because the cancer is the second leading cause of death and many factors: etiology, early diagnosis and different treatments. The observed and relative survival are the focus of this article. Methods: Through Registry Cancer Hospital Lozano Blesa Hospital of Zaragoza, as a source of information, we selected patients who entered with a diagnosis of cancer, such as. first episode between 2003-2009 whereby a 10-year period allowed (until 2014) of study after the last patient entered the cohort The diagnostic certainty was Anatomopathological. Survival time in years was calculated and these walls were considered: age, year of entry into the Register of cancer, years of survival, sex, living or dead state. From these data the absolute and relative survival and the limits of 95% confidence WAERS providing application was calculated. Results: The largest relative survival at five years were 94% of testicular cancer (LC: 95%, 81%, 194%); breast cancer 92% (LC: 91.6%, 101%); cervix 88% (LC: 71-105); prostate cancer 85% (LC: 77%, 93%) and worst in lung cancer 1% (LC: 0,5%); brain 17% (LC: 12%, 25%), stomach 22% (LC: 17%, 29%) and 21% pancreas (LC: 14%, 32%). Conclusions: A five-year survival is better for testicular cancer and worse for lungsupervivenciacancerneoplasiassurvivalAnálisis de la supervivencia relativa en cáncer. Años 2003-2009Analysis of the relative survival in cancer. Years 2003-2009article